ArticleJournal of experimental & clinical cancer research : CR2019

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.

Federica Giordano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.